These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 6508821)

  • 101. Mechanism-based model for tumor drug resistance.
    Kuczek T; Chan TC
    Cancer Chemother Pharmacol; 1992; 30(5):355-9. PubMed ID: 1505073
    [TBL] [Abstract][Full Text] [Related]  

  • 102. In vitro cytotoxic effect of N-(phosphonacetyl)-L-aspartic acid in liposome against C-26 murine colon carcinoma.
    Kim JS; Heath TD
    Arch Pharm Res; 2000 Apr; 23(2):167-71. PubMed ID: 10836745
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Hematologic and histopathologic evaluation of N-(phosphonacetyl)-L-aspartate (PALA) in mice.
    Harrison SD; Giles HD; Denine EP
    Cancer Chemother Pharmacol; 1979; 2(3):183-7. PubMed ID: 455573
    [No Abstract]   [Full Text] [Related]  

  • 104. Inhibition by N-(phosphonacetyl)-L-aspartate of aspartate transcarbamylase activity and drug-induced cell proliferation in mice.
    Yoshida T; Stark GR; Hoogenraad J
    J Biol Chem; 1974 Nov; 249(21):6951-5. PubMed ID: 4418148
    [No Abstract]   [Full Text] [Related]  

  • 105. Quantitation of the antitumor agent N-(phosphonacetyl)-L-aspartic acid in human plasma and urine by gas chromatography-mass spectrometry-selected ion monitoring.
    Branfman AR; Bruni RJ; Merrill YN; Chadwick M; Strong JM; Ervin TJ
    J Chromatogr; 1980 May; 182(2):163-9. PubMed ID: 7380909
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Pyrimidine nucleosides enhance the efficacy of inhibitors of pyrimidine biosynthesis in cultured hepatocellular carcinoma cells.
    Jacobsen LB; Putnam JE; Sawick DP; Cassady JM; Morré DJ
    Life Sci; 1988; 42(8):913-8. PubMed ID: 3343891
    [TBL] [Abstract][Full Text] [Related]  

  • 107. N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group.
    Paridaens R; Mouridsen HT; Palshof T; Cocconi G; Van Oosterom A; Rotmensz N; Sylvester R; Heuson JC; Rozencweig M
    Eur J Cancer Clin Oncol; 1982 Jan; 18(1):67-70. PubMed ID: 6211361
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Pyrimidine synthesis inhibition enhances cutaneous defenses against antibiotic resistant bacteria through activation of NOD2 signaling.
    Jatana S; Homer CR; Madajka M; Ponti AK; Kabi A; Papay F; McDonald C
    Sci Rep; 2018 Jun; 8(1):8708. PubMed ID: 29880914
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Pyridoxal 5'-phosphate, a fluorescent probe in the active site of aspartate transcarbamylase.
    Kempe TD; Stark GR
    J Biol Chem; 1975 Sep; 250(17):6861-9. PubMed ID: 239951
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Interconversion of carbamayl-L-aspartate and L-dihydroorotate by dihydroorotase from mouse Ehrlich ascites carcinoma.
    Christopherson RI; Jones ME
    J Biol Chem; 1979 Dec; 254(24):12506-12. PubMed ID: 40997
    [No Abstract]   [Full Text] [Related]  

  • 111. Synthesis and biological evaluation of S-acyl-3-thiopropyl prodrugs of N-phosphonoacetyl-L-aspartate (PALA).
    Gagnard V; Leydet A; Le Mellay V; Aubenque M; Morère A; Montero JL
    Eur J Med Chem; 2003 Oct; 38(10):883-91. PubMed ID: 14575935
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Modulation of the antitumour activity of cisplatin alone and in combination with 5-fluoro-2'-deoxyuridine by N-phosphonacetyl-L-aspartate in murine colon carcinoma no. 26.
    Van Laar JA; Mayhew EG; Cao S; Durrani FA; Peters GJ; Rustum YM
    Eur J Cancer; 1995 Jun; 31A(6):974-6. PubMed ID: 7646931
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Determination of N-(phosphonacetyl)-L-aspartic acid (PALA) in plasma and urine by high pressure liquid chromatography.
    Lankelma J; Penders PG; Leyva A; Pinedo HM
    Eur J Cancer (1965); 1980 Nov; 16(11):1483-7. PubMed ID: 7227423
    [No Abstract]   [Full Text] [Related]  

  • 114. Pyrimidine pathways enzymes in human tumors of brain and associated tissues: potentialities for the therapeutic use of N-(phosphonacetyl-L-aspartate and 1-beta-D-arabinofuranosylcytosine.
    Madani S; Baillon J; Fries J; Belhadj O; Bettaieb A; Ben Hamida M; Hervé G
    Eur J Cancer Clin Oncol; 1987 Oct; 23(10):1485-90. PubMed ID: 2824206
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Marked radiosensitization of cells in culture to X ray by 5-chlorodeoxycytidine coadministered with tetrahydrouridine, and inhibitors of pyrimidine biosynthesis.
    Perez LM; Mekras JA; Briggle TV; Greer S
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1453-8. PubMed ID: 6236189
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Kinetics of aspartate transcarbamylase from Escherichia coli for the reverse direction of reaction.
    Foote J; Lipscomb WN
    J Biol Chem; 1981 Nov; 256(22):11428-33. PubMed ID: 7028733
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Mercurial-promoted Zn2+ release from Escherichia coli aspartate transcarbamoylase.
    Hunt JB; Neece SH; Schachman HK; Ginsburg A
    J Biol Chem; 1984 Dec; 259(23):14793-803. PubMed ID: 6389552
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Treatment of psoriasis with N-phosphonacetyl-L-aspartate.
    Doyle JA; Perry HO; Rubin J; Moertel CG
    J Am Acad Dermatol; 1984 Jan; 10(1):21-4. PubMed ID: 6229552
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Detoxification of N-(phosphonoacetyl)-L-aspartate by carrot cells in suspension culture.
    Cole SC; Yon RJ
    Planta; 1985 Nov; 166(3):401-6. PubMed ID: 24241524
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Studies of the regulation and reaction mechanism of the carbamyl phosphate synthetase and aspartate transcarbamylase of bakers' yeast.
    Lue PF; Aitken DM; Kaplan JG
    Biochimie; 1976; 58(1-2):19-25. PubMed ID: 182284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.